HOVON HO162 AML
Geannuleerd
Main info
- Identificatie:
- HO162 AML
- Sponsor:
- HOVON
- Working group party:
- Leukemia
- Stadium:
- 1st lijn
- Echelon:
- Level A
- Included patients:
-
0(of 25)
- Active sites:
-
0(of 4)4 sites are pending
- Title:
A phase II multicenter study to assess the feasibility and efficacy of the addition of an interphase cycle with flotetuzumab prior to start conditioning for an allogeneic HCT in AML with detectable MRD after 2 cycles of intensive chemotherapy
Timeline
Scheduled
Actual
2021
05 jan.
Opportunity
2021
02 feb.
Development
2021
29 okt.
Submission in Progress
2021
15 nov.
Submission in Progress
2021
20 dec.
Cancelled
2022
16 jan.
Activated
2022
16 jan.
EC Approval
2022
15 feb.
First Site
2022
15 mrt.
FPI
2024
01 aug.
Endpoint Analysis
News
20 Dec 2021: The pharmaceutical company MacroGenics no longer wants to support the HO162 study.
Details
- Phase:
- Prospective Phase II study
- Monitoring Type:
- Site Evaluation Visit
- Objectives:
Registration Details
Go to eCRFParticipating Sites
Site
4 results
Order by
Accrual rate
Activation date
NL-Rotterdam-ERASMUSMC
NL-Maastricht-MUMC
NL-Groningen-UMCG
NL-Amsterdam-VUMC
= Active hospitals 
= Inactive hospitals